Abstract
This comprehensive report provides an in-depth analysis of the global ankylosing spondylitis drugs market, examining key segments such as drug classes, routes of administration, and distribution channels. It meticulously evaluates market dynamics, including technological advancements in TNF blockers and IL-17 inhibitors, alongside a detailed competitive landscape of major industry players. By analyzing regional trends across North America, Europe, and Asia-Pacific, the research delivers actionable intelligence on market growth drivers and strategic development trends.
Summary
Market Overview: Ankylosing Spondylitis Drugs Market Size and Growth
The Ankylosing Spondylitis Drugs Market emerges as a key focus in DataM Intelligence's latest in-depth analysis. Seasoned researchers harness advanced data analytics and strategic foresight to deliver unparalleled market intelligence. This insightful report meticulously explores the competitive landscape, profiling key players and their forward-thinking innovations in product development, pricing strategies, financial metrics, and global expansion initiatives.
By uncovering the driving forces, market dynamics, and disruptive trends shaping the future, this research equips industry stakeholders with the actionable insights needed to make informed decisions in an increasingly dynamic and competitive environment.
An Ankylosing Spondylitis Drugs Market is a data-driven software solution that collects, integrates, analyzes, and visualizes customer data across various touchpoints to generate actionable insights. These platforms help businesses understand customer behaviors, preferences, and purchasing patterns in real time, enabling personalized marketing, enhanced customer engagement, and data-driven decision-making.
Market Segmentation
By Drug Class
- Tumor necrosis factor (TNF) blocker:
- Adalimumab (Humira)
- Certolizumab pegol (Cimzia)
- Etanercept (Enbrel)
- Golimumab (Simponi)
- Infliximab (Remicade)
- Non-steroidal anti-inflammatory drugs:
- Ibuprofen
- Naproxen
- Disease-modifying antirheumatic drugs:
- Methotrexate
- Interleukin-17 (IL-17) inhibitor:
- Secukinumab (Cosentyx)
- Ixekizumab (Taltz)
- Others
By Route of Administration
- Parenteral
- Oral
By Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Others
Regional Analysis
- North America: U.S., Canada, Mexico
- Europe: U.K., Italy, Germany, Russia, France, Spain, The Netherlands, and Rest of Europe
- Asia-Pacific: India, Japan, China, South Korea, Australia, Indonesia, and Rest of Asia Pacific
- South America: Colombia, Brazil, Argentina, and Rest of South America
- Middle East & Africa: Saudi Arabia, U.A.E., South Africa, and Rest of Middle East & Africa
Report Scope and Coverage
This report provides a comprehensive analysis including:
- Strategic Insights: Go-to-market strategy and a neutral perspective on market performance.
- Market Dynamics: Development trends, competitive landscape analysis, supply side analysis, demand side analysis, year-on-year growth, competitive benchmarking, vendor identification, and development status.
- Customization: Customized regional/country reports as per request and country level analysis.
- Growth Opportunities: Identification of potential and niche segments and regions exhibiting promising growth.
- Quantitative & Qualitative Metrics:
- Analysis of Market Size (historical and forecast)
- Total Addressable Market (TAM)
- Serviceable Available Market (SAM)
- Serviceable Obtainable Market (SOM)
- Market Growth
- Technological Trends
- Market Share
- Market Dynamics
- Competitive Landscape and Major Players (Innovators, Start-ups, Laggard, and Pioneer)
Research Process
Both primary and secondary data sources have been used in the global Ankylosing Spondylitis Drugs Market research report. During the research process, a wide range of industry-affecting factors are examined, including:
- Governmental regulations
- Market conditions
- Competitive levels
- Historical data
- Market situation
- Technological advancements
- Upcoming developments in related businesses
- Market volatility
- Prospects, potential barriers, and challenges
Table of Contents
1 Methodology and Scope
1.1 Research Methodology
1.2 Research Objective and Scope of the Report
2 Market Definition and Overview
3 Executive Summary
3.1 Market Snippet by Drug Class
3.2 Market Snippet by Route of Administration
3.3 Market Snippet by Distribution Channel
3.4 Market Snippet by Region
4 Market Dynamics
4.1 Market Impacting Factors
4.1.1 Drivers
- 4.1.1.1 Introduction of novel products and the entry of biosimilars coupled with the increasing prevalence of the disease
4.1.2 Restraints:
- 4.1.2.1 High cost of treatment
4.1.3 Opportunity
4.1.4 Impact Analysis
5 Industry Analysis
5.1 Porter's Five Forces Analysis
5.2 Pipeline Analysis
5.3 Epidemiology
5.4 Supply Chain Analysis
5.5 Pricing Analysis
5.6 Regulatory Analysis
5.7 Unmet Needs
6 COVID-19 Analysis
6.1 Analysis of Covid-19 on the Market
6.1.1 Before COVID-19 Market Scenario
6.1.2 Present COVID-19 Market Scenario
6.1.3 After COVID-19 or Future Scenario
6.2 Pricing Dynamics Amid Covid-19
6.3 Demand-Supply Spectrum
6.4 Government Initiatives Related to the Market During Pandemic
6.5 Manufacturers Strategic Initiatives
6.6 Conclusion
7 By Drug Class
7.1 Introduction
7.1.1 Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Class
7.1.2 Market Attractiveness Index, By Drug Class
7.2 Tumor necrosis factor (TNF) blocker*
7.2.1 Introduction
7.2.2 Market Size Analysis, US$ Million, 2019-2028 and Y-o-Y Growth Analysis (%), 2020-2028
7.2.3 Adalimumab (Humira)
7.2.4 Certolizumab pegol (Cimzia)
7.2.5 Etanercept (Enbrel)
7.2.6 Golimumab (Simponi)
7.2.7 Infliximab (Remicade)
7.3 Non-steroidal anti-inflammatory drugs
7.3.1 Ibuprofen
7.3.2 Naproxen
7.4 Disease-modifying antirheumatic drugs
7.4.1 Methotrexate
7.5 Interleukin-17 (IL-17) inhibitor
7.5.1 Secukinumab (Cosentyx)
7.5.2 Ixekizumab (Taltz)
7.6 Others
8 By Route of Administration
8.1 Introduction
8.1.1 Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration
8.1.2 Market Attractiveness Index, By Route of Administration
8.2 Parenteral*
8.2.1 Introduction
8.2.2 Market Size Analysis, US$ Million, 2019-2028 and Y-o-Y Growth Analysis (%), 2020-2028
8.3 Oral
9 By Distribution Channel
9.1 Introduction
9.1.1 Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
9.1.2 Market Attractiveness Index, By Distribution Channel
9.2 Hospital Pharmacies*
9.2.1 Introduction
9.2.2 Market Size Analysis, US$ Million, 2019-2028 and Y-o-Y Growth Analysis (%), 2020-2028
9.3 Retail Pharmacies
9.4 Online Pharmacies
9.5 Others
10 By Region
10.1 Introduction
10.1.1 Market Size Analysis, US$ Million, 2019-2028 and Y-o-Y Growth Analysis (%), 2020-2028, By Region
10.1.2 Market Attractiveness Index, By Region
10.2 North America
10.2.1 Introduction
10.2.2 Key Region-Specific Dynamics
10.2.3 Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Class
10.2.4 Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration
10.2.5 Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
10.2.6 Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
- 10.2.6.1 U.S
- 10.2.6.2 Canada
- 10.2.6.3 Mexico
10.3 Europe
10.3.1 Introduction
10.3.2 Key Region-Specific Dynamics
10.3.3 Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Class
10.3.4 Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration
10.3.5 Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
10.3.6 Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
- 10.3.6.1 Germany
- 10.3.6.2 U.K
- 10.3.6.3 France
- 10.3.6.4 Italy
- 10.3.6.5 Spain
- 10.3.6.6 Rest of Europe
10.4 South America
10.4.1 Introduction
10.4.2 Key Region-Specific Dynamics
10.4.3 Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Class
10.4.4 Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration
10.4.5 Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
10.4.6 Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
- 10.4.6.1 Brazil
- 10.4.6.2 Argentina
- 10.4.6.3 Rest of South America
10.5 Asia Pacific
10.5.1 Introduction
10.5.2 Key Region-Specific Dynamics
10.5.3 Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Class
10.5.4 Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration
10.5.5 Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
10.5.6 Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
- 10.5.6.1 China
- 10.5.6.2 India
- 10.5.6.3 Japan
- 10.5.6.4 Australia
- 10.5.6.5 Rest of Asia Pacific
10.6 Middle East and Africa
10.6.1 Introduction
10.6.2 Key Region-Specific Dynamics
10.6.3 Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Class
10.6.4 Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration
10.6.5 Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
11 Competitive Landscape
11.1 Key Developments and Strategies
11.2 Company Share Analysis
11.3 Product Benchmarking
11.4 Key Companies to Watch
11.5 Company with disruptive technology
11.6 Start-Up Companies
12 Company Profiles
12.1 Novartis AG*
12.1.1 Company Overview
12.1.2 Product Portfolio and Description
12.1.3 Key Highlights
12.1.4 Financial Overview
12.2 Merck & Co., Inc
12.3 Regeneron Pharmaceuticals, Inc
12.4 Amgen Inc
12.5 AbbVie Inc
12.6 Eli Lilly and Company
12.7 UCB, S.A
12.8 Johnson & Johnson Services, Inc
12.9 Bristol-Myers Squibb Company
12.10 Pfizer Inc(*LIST NOT EXHAUSTIVE)
13 DataM Intelligence
13.1 Appendix
13.2 About Us and Services
13.3 Contact Us